Attenuation of 3,4‐methylenedioxymethamphetamine (MDMA, Ecstasy)‐induced rhabdomyolysis with α1‐ plus β3‐adrenoreceptor antagonists
Jon E. Sprague, Robert E. Brutcher, Edward Mills, David Caden, Daniel E. Rusyniak
British Journal of Pharmacology June 1, 2004 DOI: 10.1038/sj.bjp.0705823 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental animal study Peer reviewed |
|---|---|
| Population | Male Sprague–Dawley rats |
| Interventions | MDMA Prazosin SR59230A |
| Dose | MDMA 40 mg kg−1 s.c.; prazosin 100 μg kg−1 i.p.; SR59230A 5 mg kg−1 i.p. |
| Duration | 4 hours post-MDMA |
| Measures | rectal temperature, creatine kinase (CK), blood urea nitrogen (BUN), serum creatinine (sCr) |
| Topics | MDMA |
| Keywords | Rhabdomyolysis Prazosin Antagonist Pharmacology Hyperthermia Blood urea nitrogen Creatine kinase Endocrinology Creatinine |
| Citations | 53 |
| Key findings | Blocking α₁- and β₃-adrenoreceptors together prevented MDMA-induced hyperthermia and markers of rhabdomyolysis and kidney impairment in rats. |
Abstract
Studies were designed to examine the effects of α 1 ( α 1 AR)‐ plus β 3 ‐adrenoreceptor ( β 3 AR) antagonists on 3,4‐methylenedioxymethamphetamine (MDMA, Ecstasy)‐induced hyperthermia and measures of rhabdomyolysis (creatine kinase (CK)) and renal function (blood urea nitrogen (BUN) and serum creatinine (sCr)) in male Sprague–Dawley rats. MDMA (40 mg kg −1 , s.c.) induced a rapid and robust increase in rectal temperature, which was significantly attenuated by pretreatment with the α 1 AR antagonist prazosin (100 μ g kg −1 , i.p.) plus the β 3 AR antagonist SR59230A (5 mg kg −1 , i.p.). CK levels significantly increased (peaking at 4 h) after MDMA treatment and were blocked by the combination of prazosin plus SR59230A. At 4 h after MDMA treatment, BUN and sCr levels were also significantly increased and could be prevented by this combination of α 1 AR‐ plus β 3 AR‐antagonists. The results from this study suggest that α 1 AR and β 3 AR play a critical role in the etiology of MDMA‐mediated hyperthermia and subsequent rhabdomyolysis. British Journal of Pharmacology (2004) 142 , 667–670. doi: 10.1038/sj.bjp.0705823
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cited by 23
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms Pharmacological Reviews December 16, 2020
- Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens. Current Topics in Behavioral Neurosciences 2017
- The role of monoamines in the changes in body temperature induced by 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives British Journal of Pharmacology March 3, 2010
- Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans British Journal of Pharmacology March 8, 2012
- Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model* Critical Care Medicine June 1, 2005
and 18 more in the library
Cites 10
- The pharmacology of the acute hyperthermic response that follows administration of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats British Journal of Pharmacology 2002
- Cutaneous Vasoconstriction Contributes to Hyperthermia Induced by 3,4-Methylenedioxymethamphetamine (Ecstasy) in Conscious Rabbits Journal of Neuroscience November 1, 2001
- Fatal multi-organ failure after suicidal overdose with MDMA, `Ecstasy': case report and review of the literature Human & Experimental Toxicology February 1, 1999
- MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. Emergency Medicine Journal September 1, 1997
- A Fatal Trip with Ecstasy: A Case of 3,4-Methylene-Dioxymethamphetamine/ 3,4-Methylenedioxy-Amphetamine Toxicity Journal of the Royal Society of Medicine 1996
and 5 more in the library